# N4 Pharma optimisation work shows the versatility of Nuvec (Interview)

- Link: https://www.directorstalkinterviews.com/n4-pharma-optimisation-work-shows-the-versatility-of-nuvec-interview/412935680
- Published: 2020-11-06T11:04:38+00:00
- Author: Giles

**N4 Pharma plc** (LON:N4P) CEO Nigel Theobald joins DirectorsTalk to discuss its
latest operational update. Nigel talks us through the key highlights, explains why
demonstrating formulation stability is so important, the key milestones for the 
Covid-19 proof of concept programme and in vivo study with timeframes, why an orally
administered vaccine has significantly greater challenges than a subcutaneous injection
and other newsflow investors can expect in the rest of the year.

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system
for cancer and vaccine treatments using its unique silica nanoparticle delivery 
system called Nuvec®.

The business model is to partner with companies developing novel antigens for cancer
and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen
into cells to express the protein needed for the required immunity. As these products
progress through pre clinical and clinical programs, N4 Pharma will seek to receive
up front payments, milestone payments and ultimately royalty payments once products
reach the market.

Share on: